- In August 2026, Celcuity Inc. announced it had submitted a supplemental New Drug Application to the FDA for REVTORPYK (gedatolisib) to treat HR+/HER2- advanced or metastatic breast cancer with a PIK3CA mutation, based on Phase 3 VIKTORIA-1 data showing improved progression-free survival versus alpelisib plus fulvestrant.
- If approved, REVTORPYK would become the first therapy for PIK3CA-mutant advanced breast cancer that targets all class I PI3K isoforms and both mTOR complexes, potentially broadening treatment options for this sizeable patient subgroup.
- We will now examine how the sNDA filing, underpinned by positive VIKTORIA-1 progression-free survival results, may reshape Celcuity’s investment narrative.
Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
Celcuity Investment Narrative Recap
To own Celcuity, you need to believe gedatolisib can convert its targeted breast cancer profile into durable, multi‑indication revenue while the company manages sizeable losses and balance sheet risk. The new sNDA for PIK3CA‑mutant disease strengthens the near term regulatory catalyst by extending REVTORPYK’s reach, but it also concentrates execution risk further in a single asset and in timely FDA decisions that underpin the path to profitability.
The most relevant recent milestone is the July 14, 2026 FDA approval of REVTORPYK for HR+/HER2‑ advanced breast cancer without PIK3CA mutations, which effectively started Celcuity’s commercial clock. The August 26 sNDA builds directly on this by targeting the complementary PIK3CA‑mutant population, so together these events frame how quickly Celcuity might transition from a pre‑revenue, loss‑making biotech to a company with a broader, mutation‑agnostic second‑line franchise.
Yet, while these approvals expand potential reach, investors should also be aware that...
Read the full narrative on Celcuity (it's free!)
Celcuity's narrative projects $817.9 million revenue and $267.5 million earnings by 2029. This implies an earnings increase of about $460 million from -$192.9 million today.
Uncover how Celcuity's forecasts yield a $161.09 fair value, a 81% upside to its current price.
Exploring Other Perspectives
While consensus focuses on approval timing and balance sheet strain, the most optimistic analysts were already modeling about US$1.4 billion of 2029 revenue and US$562.1 million of earnings, showing how differently you and other investors may view the same FDA milestones and safety‑label risks as new clinical data emerge.
Explore 4 other fair value estimates on Celcuity - why the stock might be worth over 7x more than the current price!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Celcuity research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
- Our free Celcuity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Celcuity's overall financial health at a glance.
Contemplating Other Strategies?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- The future of work is here. Discover the 38 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com